QIAGEN Adds High Resolution Melt Kit to Epigenetics Portfolio
May 26 2009

QIAGEN Adds High Resolution Melt Kit to Epigenetics Portfolio

Pyrosequencing® technology available for further quantitative methylation and mutation analysis

Venlo, The Netherlands - May 26, 2009 - Epigentics researchers can now detect changes in methylation status in a real time format using High Resolution Melting (HRM) analysis. QIAGEN's EpiTect® HRMTM PCR kit provides a master mix format for the detection of changes in the CpG methylation status of bisulfite converted DNA. The kit is designed to run on all real-time cyclers, including the Rotor-Gene® Q, QIAGEN's real-time PCR cycler, which provides a highly specific melting curve.

HRM technology enables rapid characterization of DNA samples based on their melting behavior following PCR amplification. "HRM is ideal for screening larger numbers of samples and for the detection of changes in the methylation degree of specific DNA regions. It can be used to identify regions of interest for epigenetic researchers and then be further analyzed by methods such as Pyrosequencing, which provides quantitative sequence data," said Gerald Schock, QIAGEN's Senior Global Product Manager Epigenetics.

Epigenetics is one of the fastest-growing areas of life science research, spurring significant advancements in gene function analysis and the study of molecular diagnostics of cancers and other diseases. Epigenetics focuses on differences in gene regulation and expression resulting from DNA methylation.

"With the EpiTect product line, QIAGEN addresses the growing demand for standardized products for complete workflows in epigenetics, ranging from the already launched kits for bisulfite conversion to kits for whole bisulfitome amplification and highly sensitive methylation assays and controls," said Schock. "The EpiTect portfolio and QIAGEN automation give customers a set of standardized and convenient tools optimized for epigenetics research."

While HRM gives researchers the ability to detect changes in the degree of methylation and compare differences gene-to-gene, some research may require a closer look at the methylated region. QIAGEN's complete workflow allows researchers to continue looking at the specific sequence of those regions through Pyrosequencing. 

The instrument systems in QIAGEN's PyroMark portfolio, such as the newly launched PyroMark Q24, use proven Pyrosequencing technology for real-time, sequence-based detection and quantification for genetic testing and epigenetic methylation analysis. The PyroMark instruments combine both quantification and sequencing for highly reliable results in minutes.  The instruments also are highly suited for the discovery and analysis of allelic mutations as well as analysis and quantification of consecutive CpG sites. All PyroMark systems provide a sequencing instrument, sample preparation workstation, and reagents and controls, as well as comprehensive and flexible analysis software and a new CpG assays-design software.

Further information about the EpiTect product portfolio and PyroMark systems is available at www.qiagen.com/epigenetics.

Further information about the Rotor-Gene Q is available at www.qiagen.com/Rotor-Gene.

EpiTect products are intended for research use. No claim or representation is intended to provide information for the diagnosis, prevention or treatment of a disease.


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as the "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 3,000 people in over 30 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.


Share this page